iTeos Therapeutics (ITOS) Competitors $10.11 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$10.11 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ITOS vs. BEAM, SRPT, ARQT, ANIP, SPRY, APGE, IMCR, DYN, CDTX, and TWSTShould you be buying iTeos Therapeutics stock or one of its competitors? The main competitors of iTeos Therapeutics include Beam Therapeutics (BEAM), Sarepta Therapeutics (SRPT), Arcutis Biotherapeutics (ARQT), ANI Pharmaceuticals (ANIP), ARS Pharmaceuticals (SPRY), Apogee Therapeutics (APGE), Immunocore (IMCR), Dyne Therapeutics (DYN), Cidara Therapeutics (CDTX), and Twist Bioscience (TWST). These companies are all part of the "pharmaceutical products" industry. iTeos Therapeutics vs. Its Competitors Beam Therapeutics Sarepta Therapeutics Arcutis Biotherapeutics ANI Pharmaceuticals ARS Pharmaceuticals Apogee Therapeutics Immunocore Dyne Therapeutics Cidara Therapeutics Twist Bioscience iTeos Therapeutics (NASDAQ:ITOS) and Beam Therapeutics (NASDAQ:BEAM) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, risk, institutional ownership, profitability, valuation and earnings. Do analysts prefer ITOS or BEAM? iTeos Therapeutics currently has a consensus price target of $15.50, indicating a potential upside of 53.31%. Beam Therapeutics has a consensus price target of $48.45, indicating a potential upside of 183.36%. Given Beam Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Beam Therapeutics is more favorable than iTeos Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score iTeos Therapeutics 0 Sell rating(s) 6 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.14Beam Therapeutics 0 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 3 Strong Buy rating(s) 3.07 Which has more risk and volatility, ITOS or BEAM? iTeos Therapeutics has a beta of 1.49, suggesting that its share price is 49% more volatile than the S&P 500. Comparatively, Beam Therapeutics has a beta of 2.22, suggesting that its share price is 122% more volatile than the S&P 500. Does the media favor ITOS or BEAM? In the previous week, Beam Therapeutics had 7 more articles in the media than iTeos Therapeutics. MarketBeat recorded 10 mentions for Beam Therapeutics and 3 mentions for iTeos Therapeutics. iTeos Therapeutics' average media sentiment score of 1.11 beat Beam Therapeutics' score of 0.66 indicating that iTeos Therapeutics is being referred to more favorably in the media. Company Overall Sentiment iTeos Therapeutics Positive Beam Therapeutics Positive Which has better valuation and earnings, ITOS or BEAM? iTeos Therapeutics has higher earnings, but lower revenue than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than iTeos Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioiTeos Therapeutics$35M12.77-$134.41M-$4.67-2.16Beam Therapeutics$63.52M27.23-$376.74M-$4.50-3.80 Do institutionals & insiders have more ownership in ITOS or BEAM? 97.2% of iTeos Therapeutics shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 14.2% of iTeos Therapeutics shares are owned by company insiders. Comparatively, 3.5% of Beam Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is ITOS or BEAM more profitable? iTeos Therapeutics has a net margin of 0.00% compared to Beam Therapeutics' net margin of -661.31%. iTeos Therapeutics' return on equity of -33.26% beat Beam Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets iTeos TherapeuticsN/A -33.26% -28.16% Beam Therapeutics -661.31%-43.15%-31.06% SummaryBeam Therapeutics beats iTeos Therapeutics on 10 of the 17 factors compared between the two stocks. Get iTeos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ITOS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ITOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ITOS vs. The Competition Export to ExcelMetriciTeos TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$446.96M$3.12B$5.70B$9.79BDividend YieldN/A2.21%3.77%4.10%P/E Ratio-2.1620.7630.8625.25Price / Sales12.77231.85403.9088.50Price / CashN/A41.5625.2228.45Price / Book0.639.759.516.00Net Income-$134.41M-$54.74M$3.26B$265.34M7 Day PerformanceN/A8.09%4.49%2.81%1 Month Performance-1.46%7.70%5.18%1.50%1 Year Performance-32.33%18.13%31.98%25.46% iTeos Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ITOSiTeos Therapeutics2.8019 of 5 stars$10.11flat$15.50+53.3%-32.3%$446.96M$35M-2.1690Positive NewsBEAMBeam Therapeutics2.3632 of 5 stars$17.17-2.6%$48.45+182.2%-27.1%$1.78B$63.52M-3.82510SRPTSarepta Therapeutics4.595 of 5 stars$17.94-1.6%$44.17+146.2%-83.7%$1.78B$1.90B-20.621,372Trending NewsAnalyst ForecastShort Interest ↑Gap DownARQTArcutis Biotherapeutics1.6423 of 5 stars$14.19-3.9%$19.80+39.5%+98.9%$1.77B$196.54M-18.92150Positive NewsANIPANI Pharmaceuticals3.1184 of 5 stars$84.88+4.2%$84.75-0.2%+45.7%$1.77B$614.38M-110.23600Analyst UpgradeHigh Trading VolumeSPRYARS Pharmaceuticals2.4461 of 5 stars$16.38-6.4%$31.00+89.3%+9.0%$1.72B$89.15M-102.3790Earnings ReportAnalyst RevisionAPGEApogee Therapeutics2.8809 of 5 stars$34.65-2.1%$99.00+185.7%-17.6%$1.63BN/A-9.6391Earnings ReportIMCRImmunocore1.9423 of 5 stars$31.89-0.3%$58.00+81.9%-9.7%$1.61B$310.20M-79.73320Positive NewsDYNDyne Therapeutics3.426 of 5 stars$11.24+0.7%$34.94+210.8%-72.7%$1.59BN/A-2.91100CDTXCidara Therapeutics3.5147 of 5 stars$62.00flat$64.14+3.5%+409.9%$1.57B$1.27M-5.5790TWSTTwist Bioscience4.0641 of 5 stars$27.63+7.8%$49.40+78.8%-35.4%$1.55B$312.97M-19.06990Positive News Related Companies and Tools Related Companies BEAM Competitors SRPT Competitors ARQT Competitors ANIP Competitors SPRY Competitors APGE Competitors IMCR Competitors DYN Competitors CDTX Competitors TWST Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ITOS) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredGENIUS Act: Cancel Your Money?They said digital dollars were off the table. But with the GENIUS Act now federal law, private corporations—no...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iTeos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share iTeos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access